



available at [www.sciencedirect.com](http://www.sciencedirect.com)  
**Clinical Immunology**  
[www.elsevier.com/locate/yclim](http://www.elsevier.com/locate/yclim)



REVIEW

# Thymus transplantation

M. Louise Markert <sup>a,b,\*</sup>, Blythe H. Devlin <sup>a</sup>, Elizabeth A. McCarthy <sup>a</sup>

<sup>a</sup> Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA

<sup>b</sup> Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA

Received 1 December 2009; accepted with revision 12 February 2010

Available online 16 March 2010

**KEYWORDS**

Thymus transplantation;  
 DiGeorge;  
 22q11.2;  
 Athymia

**Abstract** Thymus transplantation is a promising investigational therapy for infants born with no thymus. Because of the athymia, these infants lack T cell development and have a severe primary immunodeficiency. Although thymic hypoplasia or aplasia is characteristic of DiGeorge anomaly, in “complete” DiGeorge anomaly, there is no detectable thymus as determined by the absence of naive (CD45RA<sup>+</sup>, CD62L<sup>+</sup>) T cells. Transplantation of postnatal allogeneic cultured thymus tissue was performed in sixty subjects with complete DiGeorge anomaly who were under the age of 2 years. Recipient survival was over 70%. Naive T cells developed 3–5 months after transplantation. The graft recipients were able to discontinue antibiotic prophylaxis, and immunoglobulin replacement. Immunosuppression was used in a subset of subjects but was discontinued when naive T cells developed. The adverse events have been acceptable with thyroid disease being the most common. Research continues on mechanisms underlying immune reconstitution after thymus transplantation.

© 2010 Elsevier Inc. All rights reserved.

**Contents**

Introduction . . . . .	237
Methods . . . . .	238
Thymus tissue procurement. . . . .	238
Thymus donor screening . . . . .	238
Thymus tissue processing . . . . .	238
Thymus transplantation . . . . .	238
Use of immunosuppression in thymus allograft recipients . . . . .	238
Results . . . . .	238
Subject population. . . . .	238
Outcomes . . . . .	239
Survival . . . . .	239
Immune outcomes . . . . .	239

\* Corresponding author. Box 3068, Duke Univ. Med. Ctr., Durham, N.C. 27710, USA. Fax: +1 919 681 8676.  
 E-mail address: [marke001@mc.duke.edu](mailto:marke001@mc.duke.edu) (M.L. Markert).

Immune outcomes in special circumstances . . . . .	242
Adverse events . . . . .	243
Immunologic mechanisms underlying allogeneic thymus transplantation . . . . .	243
Summary . . . . .	244
Acknowledgments . . . . .	244
References . . . . .	244

## Introduction

Thymus transplantation is an investigational treatment for pediatric patients with profound primary immune deficiency due to primary athymia and the resulting lack of functional T cells [1–4]. To achieve reconstitution of the T cells, cultured postnatal allogeneic thymus tissue slices are transplanted into the quadriceps muscles of the athymic recipient [4]. Recipient bone marrow stem cells migrate to the allograft where they develop into naive T cells. Thymopoiesis is observed in biopsies of the transplanted thymus within 2 months of transplantation [5] and naive T cells are detected in the peripheral blood approximately 3–5 months after transplantation [6,7]. At the current time in the United States, thymus transplantation is conducted under an Investigational New Drug application with the Food and Drug Administration and all protocols are approved by the Duke Institutional Review Board. The purpose of this review was to provide an updated summary of the subject population that may benefit from thymus transplantation, the methods used, and the clinical and immune outcomes.

Children with congenital athymia are candidates for thymus transplantation. Athymia is a rare condition and occurs in infants with 1) complete DiGeorge anomaly [1,8–11] and 2) Foxn1 deficiency [12–15]. This review focuses on thymus transplantation in children with complete DiGeorge anomaly.

DiGeorge anomaly is characterized by congenital heart disease, hypoparathyroidism and thymic hypoplasia or athymia [10,11,16]. Other findings that have been observed in patients with DiGeorge anomaly include cleft lip and/or palate, club feet, single kidney, esophageal atresia, butterfly vertebra, rib anomalies, and laryngomalacia [10,11]. Most children with clinical findings of DiGeorge anomaly have a small thymus, low T cell numbers but relatively normal T cell function [17–20]. This condition is termed “partial” DiGeorge anomaly and these children do not require thymus transplantation.

In approximately 1% of children with DiGeorge anomaly, there is an absence of functional thymus. This condition is termed “complete” DiGeorge anomaly and is fatal with almost all children dying by the age of 2 years due to infections [1,8,20]. In children with the clinical findings of DiGeorge anomaly, the diagnosis of athymia is made by examination of the blood to assess the numbers of T cells and their phenotype. Complete DiGeorge anomaly is defined as either having fewer than 50 T cells/mm<sup>3</sup> or having fewer than 50 naive (CD45RA<sup>+</sup> CD62L<sup>+</sup>) T cells/mm<sup>3</sup> [1]. Because of their profound immunodeficiency, children with complete DiGeorge anomaly are maintained on immunoglobulin replacement and antibiotic prophylaxis for pneumocystis until immunoreconstitution is achieved.

There are two phenotypes of complete DiGeorge anomaly, typical and atypical [21]. Likely, all children with complete DiGeorge anomaly are born with the “typical” phenotype, which is characterized by fewer than 50 T cells/mm<sup>3</sup>, no rash, and no lymphadenopathy. At some point after birth, children with complete DiGeorge anomaly may switch from the “typical” complete DiGeorge anomaly phenotype to an “atypical” complete DiGeorge anomaly phenotype, which is characterized by fewer than 50/mm<sup>3</sup> naive T cells, a rash associated with T cell infiltration of the skin, lymphadenopathy, and circulating oligoclonal T cells [21]. The atypical phenotype can be considered a subgroup of Omenn syndrome [22,23]. The findings in typical and atypical complete DiGeorge anomaly are contrasted in Table 1 [21,24,25]. The peripheral blood T cells found in atypical DiGeorge anomaly are characterized by i) oligoclonality in which up to 75% or higher of the T cells may represent one clone, ii) lack of expression of the naive T cell marker CD45RA, iii) expression of the  $\alpha\beta$  T cell receptor (TCR), and iv) lack of maternal T cells. The oligoclonal T cells can be predominantly CD4 single positive, CD8 single positive, or CD4<sup>+</sup>CD8<sup>+</sup> double negative cells; the numbers of these cells range from low to high for age. Functionally, these T cells may proliferate in response to mitogens, such as phytohemagglutinin, but they are not protective against opportunistic infections. Although the long

**Table 1** Characteristics of typical and atypical complete DiGeorge anomaly.

Characteristic	Typical	Atypical	Reference
Number of naive (CD45RA <sup>+</sup> CD62L <sup>+</sup> ) T cells	<50/mm <sup>3</sup>	<50/mm <sup>3</sup> <sup>a</sup>	[1]
Rash with T cells in skin biopsy	No	100%	[21,24]
Lymphadenopathy	No	>90%	[21]
Hepatosplenomegaly with T cell infiltration on biopsy	No	Rare	[25]
Circulating oligoclonal T cells	Usually none	100% can be over 20,000/mm <sup>3</sup>	[1,6,7,21]

<sup>a</sup> For subjects with very high T cell numbers, the criterion used is “<5% of total T cells”.

term outcomes of thymus transplantation in typical and atypical complete DiGeorge subjects are similar, in this review some thymus transplantation outcomes are illustrated separately for those two groups of subjects because of differences in the use of immunosuppressive drugs during the peritransplantation period.

## Methods

### Thymus tissue procurement

Thymus tissue is frequently removed by pediatric cardiac surgeons to access the surgical field in infants with congenital heart disease [1,4]. At Duke, this otherwise discarded tissue is retrieved from the operating room by our laboratory staff and processed promptly. The thymus tissue is used for transplantation only if the donor is under the age of 9 months and the parents of the donor give informed consent. Older infants are not used as donors for two reasons. First, thymuses become more fibrotic with age [26,27], which makes the tissue more difficult to slice. Second, viral infections, such as cytomegalovirus (CMV), human herpes virus 6 (HHV6), and Epstein Barr virus (EBV), increase in frequency with age and are deleterious for immune deficient thymus recipients [28–32].

### Thymus donor screening

All thymus donors and thymus tissue undergo standard donor infectious disease screening as required by the Food and Drug Administration for cell and tissue based products [33,34]. Screening includes assays for HIV, hepatitis B and C, human T-lymphotropic virus, types I and II, and *Treponema pallidum*. Screening also covers exposure and lifestyle questionnaires and family history. If the donor is less than 1 month of age, screening assays are performed primarily on blood from the biologic mother. If the donor is over 1 month old, screening is performed on both the donor and the donor's mother. Additional studies include testing the donor for EBV and CMV by PCR and antibody assays and testing the donor's mother for Epstein Barr virus (EBV) antibodies. The donor tissue is rejected if the donor, donor tissue, or donor's mother tests positive for any viral or infectious agent. Donor tissue is also rejected if the donor has EBV or CMV antibodies not present in the mother or if the antibody patterns in mother or donor suggest acute infection in either individual.

To confirm normal thymus function in the donor, the donor's blood is examined by flow cytometry to insure that the donor has greater than 50% naive (CD45RA<sup>+</sup>CD62L<sup>+</sup>) T cells. Other exclusions include 22q11.2 hemizyosity or Down syndrome in the thymus donor and autoimmune disease in primary relatives. HLA and ABO typing are done but matching is not required.

### Thymus tissue processing

In the laboratory, thymus tissue is aseptically sliced into pieces approximately 15 by 15 mm and 0.5 mm thick and held in tissue culture (5% CO<sub>2</sub>, 37 °C) floating on nitrocellulose filters which rest on surgical sponges in the presence of nutrient

medium in tissue culture dishes [34,35]. Every day during the 12 to 21 day culture period, the medium is aspirated from each plate and new medium is added by dripping onto the tissue slices. The dripping facilitates the removal of donor thymocytes, which could theoretically cause graft versus host disease in the recipient.

The sterility of the thymus cultures is assured by aseptic handling and collection of multiple samples of the culture medium throughout the culture period [34]. These samples are tested for bacteria, mycoplasma and fungus. No more than 24 h before transplantation, a sample of the culture medium must be shown to be free of endotoxin. A gram stain to test for microbial contamination is done immediately prior to the transplantation surgery.

To confirm the donor thymus tissue is normal in appearance and structure, a sample is collected on the day of harvest and 4 to 9 days before transplantation and evaluated by immunohistochemistry. The tissue must have the characteristics of normal thymus, such as lacy cytokeratin and Hassall bodies. Transplantation into the recipient occurs after 2–3 weeks of culture and after all evaluations are complete.

### Thymus transplantation

A pediatric surgeon transplants the donor thymus tissue into the quadriceps muscles of the athymic recipient in the hospital operating room [4]. The surgeon creates individual pockets in the quadriceps muscle for each tissue slice, utilizing both quadriceps muscles [4].

### Use of immunosuppression in thymus allograft recipients


The use of immunosuppression is dictated by the phenotype of the subject [1]. Subjects with typical complete DiGeorge anomaly do not have T cells or T cell function [1,6], thus they do not have the cells that can effect graft rejection and no immunosuppression is needed. Immunosuppression is used in subjects with atypical complete DiGeorge anomaly [1]. The oligoclonal T cells can destroy the thymus allograft before immune reconstitution occurs [5].

Immunosuppression for atypical complete DiGeorge anomaly subjects is started when the diagnosis of atypical complete DiGeorge anomaly is first made and typically includes treatment with calcineurin inhibitors, cyclosporine or tacrolimus. On days –5, –4 and –3 prior to thymus transplantation, atypical patients are treated with rabbit anti-thymocyte globulin (2 mg/kg/dose for 3 daily doses) [1]. Steroids, diphenhydramine, and acetaminophen are also given to decrease the cytokine storm that can be associated with administration of rabbit anti-thymocyte globulin. The calcineurin inhibitor is continued after thymus transplantation until the naive T cells reach over 10% of total T cell numbers. The calcineurin inhibitor is then weaned over the next 8–10 weeks.

## Results

### Subject population

Seventy-two infants with complete DiGeorge anomaly were consented for thymus transplantation. Each subject met



**Figure 1** Kaplan Meier survival curve of subjects with complete DiGeorge anomaly who underwent thymus transplantation. Forty-three of sixty transplanted subjects survive.

criteria for athymia plus had one of the following: congenital heart disease, hypoparathyroidism, 22q11.2 or CHARGE association [1]. In this subject population, slightly less than half of subjects were hemizygous at 22q11.2. This percentage is consistent with a recent report of 55% 22q11.2 hemizygosity in which DiGeorge anomaly patients were defined based on clinical and immunologic findings [36].

Twelve of the 72 consented subjects did not undergo transplantation. Typically the decision to not transplant was due to death of the subject or medical conditions that increased the risk of transplantation surgery [1].

## Outcomes

### Survival

Because the profound immune deficiency of athymia leads to death from infection usually before the age of 2 years, survival was the primary end point of the clinical studies. Of 60 subjects who underwent thymus transplantation, 43 (72%) are alive at this time (Fig. 1). The median survival of the 43 subjects alive at this time is 4.7 years. (One of the 43 is within 6 months of transplantation.) Of the 49 subjects who were transplanted over 2 years ago, the 2 year survival rate was 73%, 36 of 49. (Two subjects subsequently died after the 2

year time point.) The etiologies of early deaths (within one year of transplantation) are detailed in Table 2.

Two subjects died more than 1 year after thymus transplantation. One subject had an excellent immune outcome in terms of reconstitution of T cell numbers and function but also had congenital heart disease. The subject died suddenly of a presumed cardiac arrhythmia at 4.4 years after thymus transplantation. The second subject met the criteria for complete DiGeorge anomaly (congenital heart disease with absence of T cells) but also had ectodermal dysplasia with an ill-defined, recurrent coagulopathy. After thymus transplantation, this subject developed naïve T cells and a diverse T cell receptor repertoire. The T cells had proliferative responses to mitogens and anti-CD3 but the T cells did not proliferate in response to antigens. The inability of the T cells to respond to antigens likely contributed to the recurrent infections that this child had after thymus transplantation. The subject died of complications from infections and coagulopathy 7.6 years after transplantation.

### Immune outcomes

Immune outcomes are assessed after thymus transplantation by examining biopsies of the allografts by immunohistochemistry; monitoring the peripheral blood for naïve T cells and other T cell phenotypic markers; assessing diversity of the T cell receptor beta gene variable (TCR $\beta$ V) region diversity; assessing T cell proliferative responses and measuring B cell antibody responses to antigens. Summaries of each are provided below.

**Allograft biopsies.** Biopsies of the allografts are usually performed 2 months after thymus transplantation. Immunohistochemical evaluations of allograft biopsies have been published and confirm thymopoiesis with the presence of cortical CD1a<sup>+</sup>Ki-67<sup>+</sup>CD3<sup>+</sup> thymocytes associated with thymic epithelium [2,5,25,37]. Some biopsies reveal a distinct thymus medulla with Hassall bodies [4,5,7,38]. Finding thymopoiesis on biopsy supports the conclusion that appearance of circulating T cells is related to thymopoiesis in the graft and is not spontaneous recovery of the native thymus. If

**Table 2** Cause of death within 1 year of thymus transplantation.

Cause of death		<i>n</i>
Infection <i>n</i> =11	CMV, preexisting in 3, CMV with GVHD <sup>a</sup> from unirradiated blood given prior to transfer for thymus transplantation in 1 of the 3	4
	RSV (preexisting in 1)	2
	Adenovirus (preexisting)	1
	Aspergillus pneumonia, related to immunosuppression given for adverse event of enteritis/colitis	1
	Unspecified infection	3
Bleeding problems <i>n</i> =3	Hemorrhage during unrelated surgery, associated with calcium accretion in vessel associated with previous intravenous calcium therapy	1
	Intracerebral hemorrhage associated with an unspecified infection	1
	Intracerebral hemorrhage (patient on enoxaparin because of preexisting clotting problem, also had preexisting bleeding problem; patient with palliated congenital heart disease)	1
Respiratory failure <i>n</i> =1	Respiratory failure secondary to chronic ventilation required because of congenital rib anomalies	1

<sup>a</sup> Abbreviations: GVHD, graft versus host disease; RSV, respiratory syncytial virus.

the native thymus did recover and produce T cells, those new T cells would quickly reject the donor allograft. Data from the biopsy are usually the first indication that the transplanted thymus tissue is functioning properly. In subjects with atypical complete DiGeorge anomaly, maternal engraftment, or viral infections such as HHV6 that could affect thymic development, the biopsy information is particularly important for the subject's family and for making decisions regarding allowing the subject to return to the care of their local doctor.


**T cell counts.** The numbers of CD3<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> T cells reach a peak between 1 and 2 years after transplantation and then stabilize [1]. The numbers are usually below the 10th percentile for age [39]. These data have been published for typical and atypical complete DiGeorge anomaly subjects and are similar for the two groups [1]. Molecular and/or cytogenetic testing has shown that the T cells that develop after thymus transplantation are genetically recipient in all subjects tested to date ( $n=31$ ).

Circulating naive (CD45RA<sup>+</sup>CD62L<sup>+</sup>) T cells are first detected 3–5 months after thymus transplantation (Fig. 2) [3]. As can be seen in Fig. 2, naive T cell numbers appear to reach their peak by 2 years after transplantation. Using general estimating equations (GEE) analysis, we showed that the naive CD4<sup>+</sup> numbers begin to decrease 2 years after transplantation ( $p=0.02$ ). The numbers for naive CD8<sup>+</sup> T cells remain stable after year 2.

Although the naive CD4<sup>+</sup> T cell counts remain below the 10th percentile for age, the numbers are only slightly lower than the numbers of naive CD4<sup>+</sup> T cells in children with partial DiGeorge anomaly [17]. Naive CD8<sup>+</sup> T cell counts are well below the 10th percentile for age after thymus transplantation. The transplanted subjects' naive CD8<sup>+</sup> T cell counts are approximately half of the naive CD8<sup>+</sup> counts of children with partial DiGeorge anomaly. The low level of the naive T cells in both the naturally occurring partial DiGeorge anomaly patients and the complete DiGeorge anomaly subjects who undergo transplantation may be the result of low thymus output in both groups, possibly due to small thymus size.

Of note, only one of 43 subjects who survived to 1 year after transplantation did not develop naive T cells by 15 months after transplantation. This subject is now lost to follow-up. The subject had a cardiac arrest secondary to hypocalcemia 2 months after transplantation. The subject reportedly developed autoimmune hepatitis at 8 months after transplantation with elevated ALT and AST and was treated with azathiaprine and steroids. As of our last contact, the subject was not weaned off these medications.

**T cell function.** As previously reported, the T cell proliferative responses to the mitogen phytohemagglutinin (PHA) are normal in all thymus transplant recipients who develop naive T cells [1]. Most subjects have normal responses to soluble CD3. The subgroup of subjects with low proliferative responses to CD3 has no obvious clinical



**Figure 2** Naive CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts after thymus transplantation. Each subject's data are on a single line. The 10th and 90th percentiles for children of this age in years are indicated by the dashed bold lines, and the mean is indicated by the solid bold line [39]. All subjects who survive over 1 year after transplantation are included. The left panels include the subjects who did not receive peritransplantation immunosuppression; the right panels include the subjects who did receive peritransplantation immunosuppression.



problems (Fig. 3). The tetanus toxoid proliferative response increased in all subjects after they were immunized between the 1st and 3rd year after transplantation (Fig. 3).

**T cell diversity.** T cell diversity was assessed by spectratyping of the T cell receptor variable beta chain. Both typical and atypical subjects develop diverse repertoires after thymus transplantation [3,6,7] and the diverse repertoire persists for many years [1].

**B cell function.** Immunoglobulin synthesis and antibody formation develops after thymus transplantation. Table 3 includes a summary of immunoglobulin levels and antibody formation in the 42 subjects who are alive past 6 months plus the 2 subjects who died after 1 year (total of 44).


Until 2009, all subjects were maintained on immunoglobulin replacement for 2 years. At that time, if the T cell proliferative response to tetanus toxoid (after immunization) was over 10 fold, the replacement was stopped and antibody responses to tetanus toxoid and unconjugated pneumococcal immunizations were obtained. All subjects tested had a normal antibody response to tetanus and a normal response to one pneumococcal serotype and, thus, were not restarted on replacement. In 2009, the criteria for stopping immunoglobulin replacement were changed to i) greater than 9 months after transplantation, ii) normal trough IgG level for age, proliferative response to phytohemagglutinin of over 100,000 counts per minute, and iii) no ongoing immunosuppression. Two months after stopping the immunoglobulin

replacement, an IgG trough has to be normal for age or the immunoglobulin replacement is restarted.

Ten subjects in Table 3 remain on immunoglobulin replacement. Six are within 2 years of transplantation and have not weaned off immunosuppression or completed necessary immune function testing required prior to stopping the immunoglobulin replacement. Two are maintained on immunoglobulin replacement by the local physician although they meet criteria to stop replacement. One subject never developed T cell proliferative responses to antigens. That subject had ectodermal dysplasia and died at 7.6 years after transplantation. One subject was lost to follow-up (as discussed above).

Although most subjects have come off immunoglobulin replacement and have normal levels of serum immunoglobulins and protective levels of tetanus toxoid antibodies, there appears to be a high percentage of subjects with low serum IgM (Table 3). The IgM isohemagglutinin responses were assessed. Of the 18 subjects tested for anti-A isohemagglutinins, only seven had normal levels of isohemagglutinins (Fig. 4). Of the 25 subjects tested for anti-B isohemagglutinins, only 13 had normal levels of anti-B (Fig. 4). We assessed whether there was a correlation of low isohemagglutinins with low serum IgM but the relationship was not significant ( $p=0.2$  for both anti-A and anti-B, one tailed Fisher exact test).

Although not included in Table 3, of the 20 subjects tested with an unconjugated pneumococcal vaccine (prior to conjugated pneumococcal vaccination) all made positive



**Figure 3** T cell proliferative responses to soluble CD3 and tetanus toxoid after thymus transplantation. The responses to soluble CD3 are in the upper panels and responses to tetanus toxoid are in the lower panels. The responses to tetanus toxoid include time points before and after immunization with tetanus toxoid. The subjects who received immunosuppression are on the right and those without immunosuppression are on the left. All subjects who have been tested are shown. The mean and 2 standard deviations below the mean (calculated with log transformed data) are based on the healthy adult volunteers run in these assays.

**Table 3** B cell function.

Serum immunoglobulin (Ig) levels (number of subjects evaluated) <sup>a</sup>	High level	Normal level	Low level	On IVIG (cannot evaluate)
IgG (34)	2 (6%)	32 (94%)	0 (0%)	10
IgA levels (44)	10 (23%)	30 (68%)	4 (9%)	
IgM levels (44)	4 (9%)	30 (68%)	10 (23%)	
IgE levels (44)	9 (20%)	32 (73%)	3 (7%)	
Tetanus titers <sup>a</sup>	Normal	Low	Not tested	On IVIG (cannot evaluate)
	24 (100%)	0 (0%)	10	10
Isohemagglutinins <sup>b</sup> (number of subjects evaluated)	Normal	Low	Absent	
Anti-A (18)	7 (39%)	10 (56%)	1 (6%)	
Anti-B (25)	13 (52%)	6 (24%)	6 (24%)	

<sup>a</sup> Numbers tested are based on the most recent data point for all subjects who are alive past 6 months ( $n=42$ ) plus the 2 subjects who died after 1 year (total=44).

<sup>b</sup> Numbers tested are based on all subjects who have data over 2 years after transplantation. Anti-A data are for all subjects who are not blood type A and did not receive an A thymus. Anti-B data are for all subjects who are not blood type B and did not receive a B thymus. A total of 30 subjects are included in these isohemagglutinin studies.


responses to some serotypes [1]. However, the post thymus transplantation subjects did not make antibodies to as many serotypes as normal children do [40].

**ABO compatibility.** Thymus tissue was transplanted into recipients without regard to ABO compatibility. Retrospectively, we tested the impact on T cell counts of ABO incompatibility between the thymus donor and recipient. We previously reported that ABO incompatibility (e.g., an A thymus transplanted into an O recipient) results in lower CD4<sup>+</sup> T cell counts at 1 and 2 years after thymus transplantation [41]. When these correlations were extended to 3 years after transplantation, we did not find an adverse effect of ABO incompatibility on total CD3, CD4, or CD8 counts ( $p=0.5$ ,  $0.17$ , and  $0.44$ , respectively). Similarly, there was no effect of ABO incompatibility on naive CD4 or naive CD8 counts ( $p=0.48$  and  $0.14$ , respectively). These data are consistent with the ability to transplant hearts across an ABO barrier in infants less than 2 years of age

[42]. We have previously published the lack of effect of HLA matching [41].

#### Immune outcomes in special circumstances

**Maternal engraftment.** We have detected engraftment of maternal T cells in 4 subjects in the peritransplant period. In the first subject, the maternal T cells (3% of total T cells) were associated with a rash that developed at 6–9 days after transplantation. No thymus donor T cells were detected out of a total T cell count of approximately  $60/\text{mm}^3$ . The rash resolved with topical steroid therapy. For the second and third subjects, both of whom had atypical complete DiGeorge anomaly associated with rash and lymphadenopathy, less than 10% of total T cells were found to be maternal prior to transplantation. Per our standard protocol for atypical complete DiGeorge subjects, the subjects were treated with cyclosporine prior to transplantation and given 3 doses of rabbit anti-thymocyte globulin immediately prior to



**Figure 4** Production of anti-A and anti-B isohemagglutinins. The left panel includes subjects who are not blood group A and did not receive a blood group A thymus. The right panel includes subjects who are not blood group B and did not receive a blood group B thymus. For inclusion in this figure, subjects had to be tested past 2 years after transplantation. A total of 30 subjects were tested past 2 years after transplantation. Each subject is represented by a separate line or marker. Normal values are those above the solid bold line in each graph.

transplantation. Cyclosporine therapy was continued after transplantation until naive T cells increased to over 10% of the total T cells. These three subjects have excellent immune outcomes. When tested between 5 months and 3.2 years after transplantation, all T cells in these subjects were shown to be genetically recipient with no maternal cells detected. Based on the data on the first three subjects, who have developed 474–948 naive T cells/mm<sup>3</sup> by 1.9–2.5 years after transplantation, naive T cells can develop in subjects with maternal engraftment when the standard immunosuppression regimen for atypical complete DiGeorge anomaly is used. The fourth subject had a significantly higher percentage of maternal T cells, 96% (of 110 T cells/mm<sup>3</sup>), but no rash at presentation. This subject was recently transplanted and remains on calcineurin inhibitor therapy while the immune parameters are monitored.

**Human Herpes Virus 6 (HHV6) infection.** Because HHV6 suppresses hematopoiesis [43], we were concerned that HHV6 would adversely affect thymopoiesis during the reconstitution of the transplanted thymus tissue. Two subjects had HHV6 infections at the time of thymus transplantation. The first subject's allograft biopsy, obtained 5 months after transplantation, showed thymopoiesis but this subject later died from adenoviral pneumonia. The second subject developed naive T cells but has low total T cell numbers (336/mm<sup>3</sup>) at 2.6 years after transplantation. (No graft tissue was found on biopsy in this subject.) Thus, it appears that thymopoiesis can occur in the presence of HHV6 infection.

#### Adverse events

The adverse events seen most frequently after thymus transplantation are infections and autoimmune disease. Infections typically occur prior to the development of naive T cells or are associated with central venous catheters as previously reported [1].

All autoimmune diseases after thymus transplantation are considered to be adverse events related to transplantation. Thyroid disease is the most common autoimmune disease after thymus transplantation. It has occurred in 13 subjects from 0.5 to 14.4 years after transplantation (median time 1.8 years after transplantation) [1]. Two subjects presented with elevated free thyroxine (T4) and low thyroid stimulating hormone (TSH); the remaining presented with high TSH and low T4. Eleven subjects are being treated with levothyroxine; one subject is being treated with methimazole. One subject was treated with levothyroxine but at autopsy had normal thyroid histology putting the original diagnosis in doubt.

Thyroid disease has been seen in nine complete DiGeorge anomaly subjects prior to thymus transplantation [1]. Because thyroid disease has been reported to occur in 20% of adults with partial DiGeorge anomaly [44], it is possible that thyroid disease is not an adverse event caused by thymus transplantation but is a component of DiGeorge anomaly. Irrespective of the etiology, we recommend thyroid function studies every 6 months after thymus transplantation.

Cytopenias occurred in 9 subjects, all within the first 2 years of thymus transplantation [1]. Four subjects had autoimmune thrombocytopenia, one of whom presented with autoimmune thrombocytopenia before thymus transplantation and had another episode after transplantation; 2 subjects had autoimmune hemolytic anemia; 2 subjects had

autoimmune neutropenia; and one subject had all three cytopenias sequentially over a 2 month period. Some episodes were associated with HHV6 infection, adenovirus infection, or upper respiratory tract infections. Treatments included red cell transfusions, intravenous immunoglobulin, rituximab, and steroids. To date, cytopenias have not been observed beyond 2 years after thymus transplantation, which suggests that the cytopenias are related to low T cell numbers or limited T cell function early after transplantation. It is likely that cytopenias will occur more than 2 years after transplantation since autoimmune cytopenias occur in approximately 5% of children with partial DiGeorge anomaly [45–48].

The most serious adverse event was enteritis/colitis that occurred 5 months after transplantation in a subject with atypical complete DiGeorge anomaly [1]. The resulting diarrhea led to inability to maintain cyclosporine levels. When the subject returned to the transplant center for evaluation, there was denudation of the entire intestinal tract associated with T cell and neutrophil infiltration of the intestine. Large doses of immunosuppression (tacrolimus plus 15 mg/kg methylprednisolone every 12 h for 4 doses) reversed the diarrhea but the subject then died from fungal pneumonia. It is likely that this serious adverse event was related to thymus transplantation. Graft versus host disease from the donor thymus was ruled out because the T cells in the peripheral blood were recipient in origin.

Other non-life threatening autoimmune adverse events have occurred in one subject each and have been reported previously [1].

#### Immunologic mechanisms underlying allogeneic thymus transplantation

Thymus transplantation is performed without matching the major histocompatibility complex (MHC) antigens of the thymus donor to the recipient. Allogeneic thymus transplantation results in the maturation of recipient T cells that protect the recipient from infection, yet the mismatched allogeneic thymus is the site of both negative and positive selection. Understanding the biology of this process is challenging and intriguing.

Negative selection is the process in which self reactive T cells are deleted to prevent development of autoimmunity. Normally, negative selection is effected by thymic dendritic cells [49–51]. CD83<sup>+</sup> dendritic cells are located throughout the medulla and at the corticomedullary junction. These hematopoietic cells migrate to the thymus from the bone marrow. In the thymus transplant model, recipient dendritic cells likely migrate to the thymus. There, they cause clonal deletion of thymocytes with high affinity to recipient MHC and thus prevent a graft versus host like disease. The recipient dendritic cells also present tissue restricted antigens, such as those regulated by the gene autoimmune regulator (AIRE) [49,52,53]. Clonal deletion of thymocytes reacting with tissue restricted antigens prevents multiple autoimmune diseases.

Positive selection is the process by which the thymus, in particular the cortical thymic epithelium, teaches the developing thymocytes what is “self” with respect to MHC molecules [54–56]. Developing thymocytes undergo apoptosis if they have low or no affinity to self MHC as presented on the cortical thymocytes. Thymocytes that have insufficient affinity to self MHC undergo apoptosis, which prevents the production of T cells that lack affinity for self MHC and,



therefore, would not be able to respond to foreign pathogenic peptides in the context of self MHC. Thymocytes that have the appropriate affinity for self peptide:self MHC are signaled by the thymus to continue to proliferate and are thus, positively selected. When the donor thymus is mismatched to the MHC of the recipient, it is reasonable to predict that the positively selected thymocytes will be restricted to thymus donor MHC. In that case, the T cells emigrating from the thymus will not be able to interact with antigen presenting cells carrying recipient MHC in the periphery and these T cells, because of MHC mismatching, will not be able to protect the recipient from infection. The successful reconstitution of recipient T cell function in the thymus recipients forces us to consider alternative sources of cells that provide positive selection in the allogeneic donor thymus.

In the thymus transplant model, recipient cells may contribute to positive selection in the transplanted thymus. A precedent for this can be found in murine studies in which thymocytes present self MHC to each other [54,57–59]. This allows for positive selection to recipient MHC and, thus, enables new T cells to fight infection in the recipient. Another mechanism contributing to positive selection may involve recruitment of recipient epithelial cells to the allograft. In humans, recipient epithelial cells have been found in donor lungs after lung transplantation [60,61]. Evidence for recipient epithelium in the thymus after thymus transplantation has not been published for animal models and has not been evaluated in humans. Another possibility is that cortical immature dendritic cells (CD209<sup>+</sup>) from the recipient may effect positive selection after unmatched thymus transplantation and result in recipient MHC restriction [62]. Immature dendritic cells typically do not express high levels of MHC molecules, which would make these cells unlikely candidates to effect positive selection. At the present, the mechanisms of positive selection in allogeneic thymus transplantation are not defined.

### Summary

Thymus transplantation is currently performed in subjects with complete DiGeorge anomaly resulting in the survival of over 70% of treated subjects. This investigational therapy has reconstituted recipient T cells and T cell function. The adverse event profile is acceptable. These subjects provide opportunities to study mechanisms underlying the development of functional T cells in an allogeneic thymus.

### Acknowledgments

We acknowledge the research nursing and technical contributions of Stephanie Gupton, Alice Jackson, Marilyn Alexieff, Jie Li, Chia-San Hsieh, Jennifer Lonon, Julie Smith, and Anita Croasmun and the statistician assistance of Yi-Ju Li, PhD. The expert assistant of the Duke Comprehensive Cancer Center flow cytometry resource under Dr. J. Michael Cook is appreciated. We also acknowledge the support of NIH grants R01 AI 47040, R01 AI 54843, and R21 AI 60967 and the FDA Office of Orphan Product Development Grant FD-R-002606. The support of the staff of the NCCR GCRC M03 RR30 is appreciated. M.L.M. is a member of the Duke Comprehensive Cancer Center. Finally we

acknowledge the excellent clinical care of the DiGeorge anomaly subjects by the faculty and fellows of the Division of Pediatric Allergy and Immunology.

### References

- [1] M.L. Markert, B.H. Devlin, M.J. Alexieff, J. Li, E.A. McCarthy, S.E. Gupton, et al., Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants, *Blood* 109 (10) (2007 May 15) 4539–4547.
- [2] M.L. Markert, B.H. Devlin, Thymic reconstitution, in: R.R. Rich, T.A. Fleischer, W.T. Shearer, H.W. Schroeder II, A.J. Frew, C.M. Weyand (Eds.), *Clinical Immunology*, 3rd ed., Elsevier, Edinburgh, 2008, pp. 1253–1262.
- [3] M.L. Markert, B.H. Devlin, E.A. McCarthy, I.K. Chinn, L.P. Hale, Thymus transplantation, in: C. Lavinin, C.A. Moran, U. Morandi, R. Schoenhuber (Eds.), *Thymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features*, Springer-Verlag Italia, Milan, 2008, pp. 255–267.
- [4] H.E. Rice, M.A. Skinner, S.M. Mahaffey, K.T. Oldham, R.J. Ing, L.P. Hale, et al., Thymic transplantation for complete DiGeorge syndrome: medical and surgical considerations, *J. Pediatr. Surg.* 39 (11) (2004 Nov) 1607–1615.
- [5] M.L. Markert, J. Li, B.H. Devlin, J.C. Hoehner, H.E. Rice, M.A. Skinner, et al., Use of allograft biopsies to assess thymopoiesis after thymus transplantation, *J. Immunol.* 180 (9) (2008 May 1) 6354–6364.
- [6] M.L. Markert, M. Sarzotti, D.A. Ozaki, G.D. Sempowski, M.E. Rhein, L.P. Hale, et al., Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients, *Blood* 102 (3) (2003 Aug 1) 1121–1130.
- [7] M.L. Markert, M.J. Alexieff, J. Li, M. Sarzotti, D.A. Ozaki, B.H. Devlin, et al., Postnatal thymus transplantation with immunosuppression as treatment for DiGeorge syndrome, *Blood* 104 (8) (2004 Oct 15) 2574–2581.
- [8] M.L. Markert, D.S. Hummel, H.M. Rosenblatt, S.E. Schiff, T.O. Harville, L.W. Williams, et al., Complete DiGeorge syndrome: persistence of profound immunodeficiency, *J. Pediatr.* 132 (1) (1998 Jan) 15–21.
- [9] R. Hong, The DiGeorge anomaly, *Clin. Rev. Allergy Immunol.* 20 (1) (2001 Feb) 43–60.
- [10] M.E. Conley, J.B. Beckwith, J.F. Mancera, L. Tenckhoff, The spectrum of the DiGeorge syndrome, *J. Pediatr.* 94 (6) (1979 Jun) 883–890.
- [11] D.J. Barrett, A.J. Ammann, D.W. Wara, M.J. Cowan, T.J. Fisher, E.R. Stiehm, Clinical and immunologic spectrum of the DiGeorge syndrome, *J. Clin. Lab. Immunol.* 6 (1) (1981 Jul) 1–6.
- [12] S.P. Flanagan, 'Nude', a new hairless gene with pleiotropic effects in the mouse, *Genet. Res.* 8 (3) (1966 Dec) 295–309.
- [13] C. Pignata, L. Gaetaniello, A.M. Masci, J. Frank, A. Christiano, E. Matrecano, et al., Human equivalent of the mouse Nude/SCID phenotype: long-term evaluation of immunologic reconstitution after bone marrow transplantation, *Blood* 97 (4) (2001 Feb 15) 880–885.
- [14] M. Adriani, A. Martinez-Mir, F. Fusco, R. Busiello, J. Frank, S. Telese, et al., Ancestral founder mutation of the nude (FOXP1) gene in congenital severe combined immunodeficiency associated with alopecia in southern Italy population, *Ann. Hum. Genet.* 68 (Pt. 3) (2004 May) 265–268.
- [15] J. Frank, C. Pignata, A.A. Panteleyev, D.M. Prowse, H. Baden, L. Weiner, et al., Exposing the human nude phenotype, *Nature* 398 (6727) (1999 Apr 8) 473–474.
- [16] A.M. DiGeorge, Maldevelopment of the thymus, *Pediatr. Pathol.* 14 (1) (1994 Jan-Feb) 178 author reply 9–80.

- [17] J. Chinen, H.M. Rosenblatt, E.O. Smith, W.T. Shearer, L.M. Noroski, Long-term assessment of T-cell populations in DiGeorge syndrome, *J. Allergy Clin. Immunol.* 111 (3) (2003 Mar) 573–579.
- [18] L.M. Pileri, A.N. Sanford, D.M. McDonald-McGinn, E.H. Zackai, K.E. Sullivan, T-cell homeostasis in humans with thymic hypoplasia due to chromosome 22q11.2 deletion syndrome, *Blood* 103 (3) (2004 Feb 1) 1020–1025.
- [19] K.E. Sullivan, A.F. Jawad, P. Randall, D.A. Driscoll, B.S. Emanuel, D.M. McDonald-McGinn, et al., Lack of correlation between impaired T cell production, immunodeficiency, and other phenotypic features in chromosome 22q11.2 deletion syndromes, *Clin. Immunol. Immunopathol.* 86 (2) (1998 Feb) 141–146.
- [20] J. Bastian, S. Law, L. Vogler, A. Lawton, H. Herrod, S. Anderson, et al., Prediction of persistent immunodeficiency in the DiGeorge anomaly, *J. Pediatr.* 115 (3) (1989 Sep) 391–396.
- [21] M.L. Markert, M.J. Alexieff, J. Li, M. Sarzotti, D.A. Ozaki, B.H. Devlin, et al., Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases, *J. Allergy Clin. Immunol.* 113 (4) (2004 Apr) 734–741.
- [22] A.K. Junker, K.W. Chan, B.G. Massing, Clinical and immune recovery from Omenn syndrome after bone marrow transplantation, *J. Pediatr.* 114 (4 Pt. 1) (1989 Apr) 596–600.
- [23] G.S. Omenn, Familial reticuloendotheliosis with eosinophilia, *N. Eng. J. Med.* 273 (1965 Aug 19) 427–432.
- [24] M.A. Selim, M.L. Markert, J.L. Burchette, C.M. Herman, J.W. Turner, The cutaneous manifestations of atypical complete DiGeorge syndrome: a histopathologic and immunohistochemical study, *J. Cutan Pathol.* 35 (4) (2008 Apr) 380–385.
- [25] M.L. Markert, B.H. Devlin, I.K. Chinn, E.A. McCarthy, Thymus transplantation in complete DiGeorge anomaly, *Immunol. Res.* 44 (1-3) (2009) 61–70.
- [26] B.F. Haynes, M.L. Markert, G.D. Sempowski, D.D. Patel, L.P. Hale, The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection, *Annu. Rev. Immunol.* 18 (2000) 529–560.
- [27] K.G. Flores, J. Li, G.D. Sempowski, B.F. Haynes, L.P. Hale, Analysis of the human thymic perivascular space during aging, *J. Clin. Invest.* 104 (8) (1999 Oct) 1031–1039.
- [28] M.D. Yow, N.H. White, L.H. Taber, A.L. Frank, W.C. Gruber, R.A. May, et al., Acquisition of cytomegalovirus infection from birth to 10 years: a longitudinal serologic study, *J. Pediatr.* 110 (1) (1987 Jan) 37–42.
- [29] K.H. Chan, J.S. Tam, J.S. Peiris, W.H. Seto, M.H. Ng, Epstein–Barr virus (EBV) infection in infancy, *J. Clin. Virol.* 21 (1) (2001 Apr) 57–62.
- [30] H. Savolainen, I. Lautenschlager, H. Piiparinen, U. Saarinen-Pihkala, L. Hovi, K. Vetteranta, Human herpesvirus-6 and -7 in pediatric stem cell transplantation, *Pediatric Blood Cancer* 45 (6) (2005 Nov) 820–825.
- [31] E.R. Reece, J.G. Gartner, T.A. Seemayer, J.H. Joncas, J.S. Pagano, Epstein–Barr virus in a malignant lymphoproliferative disorder of B-cells occurring after thymic epithelial transplantation for combined immunodeficiency, *Cancer Res.* 41 (11 Pt. 1) (1981 Nov) 4243–4247.
- [32] M. Dictor, A. Fasth, S. Olling, Abnormal B-cell proliferation associated with combined immunodeficiency, cytomegalovirus, and cultured thymus grafts, *Am. J. Clin. Pathol.* 82 (4) (1984 Oct) 487–490.
- [33] 21CFR1271 F. Guidance for Industry, August 2007, Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). 2007.
- [34] M.L. Markert, B.H. Devlin, E.A. McCarthy, I.K. Chinn, L.P. Hale, Thymus transplantation, in: C.M.C. Lavinin, U. Morandi, R. Schoenhuber (Eds.), *Thymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features*, Springer-Verlag Italia, Milan, 2008, pp. 255–267.
- [35] R. Hong, A.L. Moore, Organ culture for thymus transplantation, *Transplantation* 61 (3) (1996 Feb 15) 444–448.
- [36] A.F. Rope, D.L. Cragun, H.M. Saal, R.J. Hopkin, DiGeorge anomaly in the absence of chromosome 22q11.2 deletion, *J. Pediatr.* 155 (4) (2009 Oct) 560–565.
- [37] M.L. Markert, D.D. Kostyu, F.E. Ward, T.M. McLaughlin, T.J. Watson, R.H. Buckley, et al., Successful formation of a chimeric human thymus allograft following transplantation of cultured postnatal human thymus, *J. Immunol.* 158 (2) (1997 Jan 15) 998–1005.
- [38] M.L. Markert, A. Boeck, L.P. Hale, A.L. Kloster, T.M. McLaughlin, M.N. Batchvarova, et al., Transplantation of thymus tissue in complete DiGeorge syndrome, *N. Eng. J. Med.* 341 (16) (1999 Oct 14) 1180–1189.
- [39] W.T. Shearer, H.M. Rosenblatt, R.S. Gelman, R. Oyomopito, S. Plaeger, E.R. Stiehm, et al., Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study, *J. Allergy Clin. Immunol.* 112 (5) (2003 Nov) 973–980.
- [40] W. Kamchaisatian, W. Wanwatsuntikul, J.W. Sleasman, N. Tangsinmankong, Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children, *J. Allergy Clin. Immunol.* 118 (6) (2006 Dec) 1336–1341.
- [41] M.L. Markert, B.H. Devlin, I.K. Chinn, E.A. McCarthy, Y.J. Li, Factors affecting success of thymus transplantation for complete DiGeorge anomaly, *Am. J. Trans.* 8 (8) (2008 Aug) 1729–1736.
- [42] X. Fan, A. Ang, S.M. Pollock-Barziv, A.I. Dipchand, P. Ruiz, G. Wilson, et al., Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation, *Nat. Med.* 10 (11) (2004 Nov) 1227–1233.
- [43] H. Isomura, M. Yamada, M. Yoshida, H. Tanaka, T. Kitamura, M. Oda, et al., Suppressing effects of human herpesvirus 6 on in vitro colony formation of hematopoietic progenitor cells, *J. Med. Virol.* 52 (4) (1997 Aug) 406–412.
- [44] A.S. Bassett, E.W. Chow, J. Husted, R. Weksberg, O. Caluseriu, G.D. Webb, et al., Clinical features of 78 adults with 22q11 Deletion Syndrome, *Am. J. Med. Genet.* 138 (4) (2005 Nov 1) 307–313.
- [45] A.F. Jawad, D.M. McDonald-McGinn, E. Zackai, K.E. Sullivan, Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome), *J. Pediatr.* 139 (5) (2001 Nov) 715–723.
- [46] A.D. DePiero, E.M. Lourie, B.W. Berman, N.H. Robin, A.B. Zinn, R.W. Hostoffer, Recurrent immune cytopenias in two patients with DiGeorge/velocardiofacial syndrome, *J. Pediatr.* 131 (3) (1997 Sep) 484–486.
- [47] S.G. Duke, W.F. McGuirt Jr., T. Jewett, M.B. Fasano, Velocardiofacial syndrome: incidence of immune cytopenias, *Arch. Otolaryngol. Head Neck Surg.* 126 (9) (2000 Sep) 1141–1145.
- [48] J.K. Davies, P. Telfer, J.D. Cavenagh, N. Foot, M. Neat, Autoimmune cytopenias in the 22q11.2 deletion syndrome, *Clin. Lab. Haematol.* 25 (3) (2003 Jun) 195–197.
- [49] A. Liston, S. Lesage, J. Wilson, L. Peltonen, C.C. Goodnow, Aire regulates negative selection of organ-specific T cells, *Nat. Immunol.* 4 (4) (2003 Apr) 350–354.
- [50] E. Palmer, Negative selection—clearing out the bad apples from the T-cell repertoire, *Nat. Rev.* 3 (5) (2003 May) 383–391.
- [51] O.M. Siggs, L.E. Makaroff, A. Liston, The why and how of thymocyte negative selection, *Curr. Opin. Immunol.* 18 (2) (2006 Apr) 175–183.
- [52] M.S. Anderson, E.S. Venanzi, Z. Chen, S.P. Berzins, C. Benoist, D. Mathis, The cellular mechanism of Aire control of T cell tolerance, *Immunity* 23 (2) (2005 Aug) 227–239.

- [53] M.S. Anderson, E.S. Venanzi, L. Klein, Z. Chen, S.P. Berzins, S.J. Turley, et al., Projection of an immunological self shadow within the thymus by the Aire protein, *Science* 298 (5597) (2002 Nov 15) 1395–1401.
- [54] A.P. Chidgey, R.L. Boyd, Thymic stromal cells and positive selection, *Apmis* 109 (7-8) (2001 Jul-Aug) 481–492.
- [55] H. von Boehmer, Positive selection of lymphocytes, *Cell* 76 (2) (1994 Jan 28) 219–228.
- [56] S.C. Jameson, K.A. Hogquist, M.J. Bevan, Positive selection of thymocytes, *Annu. Rev. Immunol.* 13 (1995) 93–126.
- [57] E.Y. Choi, K.C. Jung, H.J. Park, D.H. Chung, J.S. Song, S.D. Yang, et al., Thymocyte–Thymocyte interaction for efficient positive selection and maturation of CD4 T cells, *Immunity* 23 (4) (2005 Oct) 387–396.
- [58] W. Li, M.G. Kim, T.S. Gourley, B.P. McCarthy, D.B. Sant'Angelo, C.H. Chang, An alternate pathway for CD4 T cell development: thymocyte-expressed MHC class II selects a distinct T cell population, *Immunity* 23 (4) (2005 Oct) 375–386.
- [59] M. Bix, D. Raulet, Inefficient positive selection of T cells directed by haematopoietic cells, *Nature* 359 (6393) (1992 Sep 24) 330–333.
- [60] H. Spencer, D. Rampling, P. Aurora, D. Bonnet, S.L. Hart, A. Jaffe, Transbronchial biopsies provide longitudinal evidence for epithelial chimerism in children following sex mismatched lung transplantation, *Thorax* 60 (1) (2005 Jan) 60–62.
- [61] W. Kleeberger, A. Versmold, T. Rothamel, S. Glockner, M. Bredt, A. Haverich, et al., Increased chimerism of bronchial and alveolar epithelium in human lung allografts undergoing chronic injury, *Am. J. Pathol.* 162 (5) (2003 May) 1487–1494.
- [62] L.C. Paessens, D.M. Fluitsma, Y. van Kooyk, Haematopoietic antigen-presenting cells in the human thymic cortex: evidence for a role in selection and removal of apoptotic thymocytes, *J. Pathol.* 214 (1) (2008 Jan) 96–103.